Recent patents on anti-infective drug discovery最新文献_第9页

MERS-CoV An Emerging Viral Zoonotic Disease: Three Years After and Counting. MERS-CoV 一种新出现的病毒性人畜共患病：三年后的今天

Recent patents on anti-infective drug discovery Pub Date : 2015-04-15

Ziad A Memish

引用次数: 0

Rabies in South Asia: fighting for elimination. 南亚狂犬病:为消除而战。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150410130024

Fazle-Rabbi Chowdhury, Ariful Basher, Mohammad R Amin, Nazia Hassan, Mohammad I Patwary

{"title":"Rabies in South Asia: fighting for elimination.","authors":"Fazle-Rabbi Chowdhury, Ariful Basher, Mohammad R Amin, Nazia Hassan, Mohammad I Patwary","doi":"10.2174/1574891x10666150410130024","DOIUrl":"https://doi.org/10.2174/1574891x10666150410130024","url":null,"abstract":"South Asia is regarded as the hot spot for the tourist and travelers. Unfortunately, three big countries (India, Pakistan and Bangladesh) of this region belong to top five rabies endemic countries of the world. Around 55,000 people die of rabies every year globally and 45% of them belong to South and South East Asia. Countries are now working on the elimination of rabies by the year 2020. Elimination of animal rabies is the pivotal of controlling human rabies. Dog (primary source) registration, population control and mass vaccination are the different ways of eliminating animal rabies. Pre (for risk groups including travelers) and post-exposure vaccine is the core for controlling human rabies. Post-exposure vaccine consists of nerve tissue vaccine and tissue culture vaccine. Due to low antigenicity and post-vaccine neurological complications all countries of South Asia except Pakistan have phased out the production and use of nerve tissue vaccine. To reduce the cost intramuscular regimen is now largely replaced by intradermal regimen and equine rabies immunoglobulin will probably replace human immunoglobulin in future for category III animal bite. 'SAARC' took initiatives for rabies elimination through 'SAARC development fund' which would hopefully play a vital role in regional collaboration to make the region rabies free. ","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150410130024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33078410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

The Human Epidermal Antimicrobial Barrier: Current Knowledge, Clinical Relevance and Therapeutic Implications. 人类表皮抗菌屏障:当前的知识，临床相关性和治疗意义。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150623093446

Roshan Gunathilake

引用次数: 3

Challenges for Fish Foodborne Parasitic Zoonotic Diseases. 鱼类食源性寄生虫人畜共患病的挑战。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150504120415

Alfonso J Rodríguez-Morales

引用次数: 2

Antibiotic Susceptibility Patterns of Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase Pseudomonas aeruginosa Clinical Isolates. 广谱β -内酰胺酶与非广谱β -内酰胺酶铜绿假单胞菌临床分离株的药敏特征

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150901111312

Mostafa Akbariqomi, Sobhan Ghafourian, Morovat Taherikalani, Satar Mohammadi, Iraj Pakzad, Nourkhoda Sadeghifard

{"title":"Antibiotic Susceptibility Patterns of Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase Pseudomonas aeruginosa Clinical Isolates.","authors":"Mostafa Akbariqomi, Sobhan Ghafourian, Morovat Taherikalani, Satar Mohammadi, Iraj Pakzad, Nourkhoda Sadeghifard","doi":"10.2174/1574891x10666150901111312","DOIUrl":"https://doi.org/10.2174/1574891x10666150901111312","url":null,"abstract":"Background: Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P. aeruginosa clinical isolates.Methods: A total of 76 P.aeruginosa clinical isolates were collected from Milad hospital in Tehran, Iran, during 8 months period in 2012. P.aeruginosa clinical isolates were subjected for ESBL production by phenotypic methods. The antibiotic susceptibility patterns were identified in ESBL and non-ESBL P. aeruginosa by MIC.Results: our results demonstrated that 76.3% (n =58) isolates were resistant to more than three antibiotics and classified as MDR. The majority of MDR strains were found in ESBL producer P. aeruginosa. ceftazidim as 3rd generation of cephalosporins, ciprofloxacin, Ticarcillin and aztreonam were found as a base for definition of MDR in the current research. The effectiveness antibiotics against ESBL and non-ESBL were meropenem and amikacin, respectively.Conclusion: based on our knowledge obtained from results, both ESBL and non-ESBL P. aeruginosa were resistant to extended antibiotics and this is a major health care problem. On the other hand, MDR strains more identified in ESBL producer P .a eruginosa. Also, carabapenem resistance observed in non-ESBL producer strains. Hence, it is recommended that the MDR strains should be following up. the prescription of ceftazidim, ciprofloxacin, Ticarcillin and aztreonam should be limited.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33964116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Chikungunya, the 2014, emerging infectious diseases in the Americas. 基孔肯雅热是2014年美洲新发传染病。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408155316

Celia M Alpuche-Aranda, Hugo Lopez-Gatell

引用次数: 4

Malaria by Plasmodium knowlesi, A Zoonosis Transmitted by Vectors. 诺氏疟原虫感染的疟疾，一种由媒介传播的人畜共患病。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408155455

Jorge E Machado-Alba

引用次数: 0

Human anthrax as a re-emerging disease. 人类炭疽是一种重新出现的疾病。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150408162354

Mehmet Doganay, Hayati Demiraslan

{"title":"Human anthrax as a re-emerging disease.","authors":"Mehmet Doganay, Hayati Demiraslan","doi":"10.2174/1574891x10666150408162354","DOIUrl":"https://doi.org/10.2174/1574891x10666150408162354","url":null,"abstract":"Anthrax is primarily a disease of herbivores and the etiological agent is B. anthracis which is a gram-positive, aerobic, spore-forming, and rod shaped bacterium. Bacillus anthracis spores are highly resistant to heat, pressure, ultraviolet and ionizing radiation, chemical agents and disinfectants. For these reasons, B. anthracis spores are an attractive choice as biological agents for the use of bioweapon and/or bioterrorism. Soil is the main reservoir for the infectious agent. The disease most commonly affects wild and domestic mammals. Human are secondarily infected by contact with infected animals and contaminated animal products or directly expose to B. anthracis spores. Anthrax occurs worldwide. This infection is still endemic or hyperendemic in both animals and humans in some part of areas of the world; particularly in Middle East, West Africa, Central Asia, some part of India, South America. However, some countries are claiming free of anthrax, and anthrax has become a re-emerging disease in western countries with the intentional outbreak. Currently, anthrax is classified according to its setting as (1) naturally occurring anthrax, (2) bioterrorism-related anthrax. Vast majority of human anthrax are occurring as naturally occurring anthrax in the world. It is also a threaten disease for western countries. The aim of this paper is to review the relevant patents, short historical perspective, microbiological and epidemiological features, clinical presentations and treatment. ","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150408162354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33197375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels. 用强力霉素治疗的登革热患者显示出与IL-6和TNF水平降低相关的较低死亡率。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x10666150410153839

Terry M Fredeking, Jorge E Zavala-Castro, Pedro González-Martínez, William Moguel-Rodríguez, Ernesto C Sanchez, Michael J Foster, Fredi A Diaz-Quijano

{"title":"Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels.","authors":"Terry M Fredeking, Jorge E Zavala-Castro, Pedro González-Martínez, William Moguel-Rodríguez, Ernesto C Sanchez, Michael J Foster, Fredi A Diaz-Quijano","doi":"10.2174/1574891x10666150410153839","DOIUrl":"https://doi.org/10.2174/1574891x10666150410153839","url":null,"abstract":"Objective: To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.Methods: A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.Results: Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.Conclusion: The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574891x10666150410153839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33202365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 61

Preface. 前言。

Recent patents on anti-infective drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574891x1001150521150210

Dieter Kabelitz

引用次数: 0